Rajesh K. Malik
Net Worth

Last updated:

What is Rajesh K. Malik net worth?

The estimated net worth of Dr. Rajesh K. Malik is at least $5,844,673 as of 13 May 2024. He owns shares worth $1,155,159 as insider, has earned $620,414 from insider trading and has received compensation worth at least $4,069,100 in G1 Therapeutics, Inc..

What is the salary of Rajesh K. Malik?

Dr. Rajesh K. Malik salary is $581,300 per year as Chief Medical Officer and Senior Vice President of R&D in G1 Therapeutics, Inc..

How old is Rajesh K. Malik?

Dr. Rajesh K. Malik is 66 years old, born in 1959.

What stocks does Rajesh K. Malik currently own?

As insider, Dr. Rajesh K. Malik owns shares in one company:

Company Title Shares Price per share Total value
G1 Therapeutics, Inc. (GTHX) Chief Medical Officer and Senior Vice President of R&D 161,787 $7.14 $1,155,159

What does G1 Therapeutics, Inc. do?

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

GTHX logo
GTHX
G1 Therapeutics, Inc.
$7.14

Rajesh K. Malik insider trading

G1 Therapeutics, Inc.

Dr. Rajesh K. Malik has made 29 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently he sold 8,151 units of GTHX stock worth $39,035 on 13 May 2024.

The largest trade he's ever made was exercising 33,839 units of GTHX stock on 11 Dec 2023. As of 13 May 2024 he still owns at least 161,787 units of GTHX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 8,151 $4.79 $39,035
Option
Stock Option (Right to Buy) 28,600 $0.3 $8,580
Option
Common Stock 28,600 $0.3 $8,580
Sale
Common Stock 28,600 $4.62 $132,132
Sale
Common Stock 721 $2.94 $2,121
Sale
Common Stock 758 $3.12 $2,364
Sale
Common Stock 2,261 $3.12 $7,052
Option
Common Stock 21,439 $0.39 $8,361
Option
Stock Options (Right to Buy) 21,439 $0.39 $8,361
Sale
Common Stock 33,839 $3.54 $119,858
Option
Common Stock 12,400 $0.3 $3,720
Option
Stock Option (Right to Buy) 12,400 $0.3 $3,720
Sale
Common Stock 1,361 $2.45 $3,340
Sale
Common Stock 729 $5.41 $3,942
Sale
Common Stock 1,639 $5.58 $9,139
Option
Common Stock 14,000 $0.3 $4,200
Option
Stock Option (Right to Buy) 14,000 $0.3 $4,200
Option
Stock Options (Right to Buy) 18,000 $0.39 $7,020
Sale
Common Stock 18,000 $15.71 $282,744
Option
Common Stock 18,000 $0.39 $7,020
Sale
Common Stock 648 $5.17 $3,351
Option
Common Stock 10,000 $0.3 $3,000
Option
Stock Option (Right to Buy) 10,000 $0.3 $3,000
Sale
Common Stock 1,445 $10.61 $15,334
Option
Stock Option (Right to Buy) 10,000 $0.3 $3,000
Option
Common Stock 10,000 $0.3 $3,000
Option
Common Stock 15,000 N/A N/A
Sale
Common Stock 15,000 N/A N/A
Option
Stock Options (Right to Buy) 15,000 N/A N/A
Option
Common Stock 15,000 N/A N/A
Option
Stock Options (Right to Buy) 15,000 N/A N/A
Sale
Common Stock 15,000 N/A N/A
Sale
Common Stock 15,000 N/A N/A
Option
Stock Options (Right to Buy) 10,405 N/A N/A
Option
Common Stock 15,000 N/A N/A
Option
Stock Option (Right to Buy) 4,595 N/A N/A
Option
Common Stock 15,000 N/A N/A
Option
Stock Options (Right to Buy) 3,100 N/A N/A
Option
Common Stock 3,100 N/A N/A
Option
Common Stock 15,000 N/A N/A
Option
Stock Option (Right to Buy) 15,000 N/A N/A
Sale
Common Stock 15,000 N/A N/A
Option
Common Stock 9,000 N/A N/A
Sale
Common Stock 9,000 N/A N/A
Option
Stock Option (Right to Buy) 9,000 N/A N/A
Option
Stock Options (Right to Buy) 2,500 N/A N/A
Option
Common Stock 2,500 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Stock Options (Right to Buy) 5,000 N/A N/A
Option
Common Stock 7,000 N/A N/A
Option
Stock Options (Right to Buy) 7,000 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Sale
Common Stock 3,776 N/A N/A
Option
Common Stock 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Sale
Common Stock 3,776 N/A N/A
Option
Common Stock 3,776 N/A N/A
Sale
Common Stock 3,776 N/A N/A
Option
Common Stock 10,076 $2.28 $22,973
Option
Common Stock 10,076 N/A N/A
Option
Stock Option (Right to Buy) 6,300 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Sale
Common Stock 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Option
Common Stock 3,776 N/A N/A
Option
Common Stock 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Sale
Common Stock 3,776 N/A N/A
Option
Common Stock 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Sale
Common Stock 3,776 N/A N/A
Sale
Common Stock 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Option
Common Stock 3,776 N/A N/A
Option
Stock Options (Right to Buy) 4,200 N/A N/A
Option
Common Stock 4,200 N/A N/A
Sale
Common Stock 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Option
Common Stock 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Sale
Common Stock 3,776 N/A N/A
Option
Common Stock 3,776 N/A N/A
Option
Common Stock 3,776 $2.28 $8,609
Sale
Common Stock 3,776 N/A N/A
Option
Common Stock 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 $2.28 $8,609
Option
Stock Options (Right to Buy) 4,200 N/A N/A
Option
Common Stock 4,200 N/A N/A
Option
Common Stock 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 $0.35 $1,303
Sale
Common Stock 3,776 N/A N/A
Option
Stock Options (Right to Buy) 3,776 N/A N/A
Option
Common Stock 3,776 N/A N/A
Sale
Common Stock 3,776 N/A N/A

G1 Therapeutics key executives

G1 Therapeutics, Inc. executives and other stock owners filed with the SEC: